Biomarkers in acute and chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 2, 2008, Pages 127-132

  Nickolas, Thomas L ^a   Barasch, Jonathan ^a   Devarajan, Prasad ^b,c  

^a Columbia University Medical Center ^*  (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MLC 7022 ^*  (United States)

Author keywords

Acute kidney injury; Acute renal failure; Biomarkers; Chronic kidney disease; Cystatin C; Neutrophil gelatinase associated lipocalin

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; INTERLEUKIN 18; LIPOCALIN;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION; HUMAN; MOLECULAR WEIGHT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SODIUM EXCRETION; TREATMENT INDICATION;

ACUTE-PHASE PROTEINS; ARGININE; BIOLOGICAL MARKERS; CYSTATINS; FATTY ACID-BINDING PROTEINS; HUMANS; INTERLEUKIN-18; KIDNEY FAILURE, ACUTE; LIPOCALINS; MEMBRANE GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 39149134872     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f4e525     Document Type: Review

References (44)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930-936.
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813-818.
3. Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int 2006; 70:1120-1126.
4. Parikh CR, McSweeney P, Schrier RW. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005; 67:1999-2005.
5. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17:1503-1520. This is a comprehensive review of the pathophysiologic mechanisms that underlie AKI, with implications for biomarker discovery and emerging therapies.
6. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007; 156:203-212. A review of novel biomarkers of AKI is presented.
7. Zhou H, Hewitt SM, Yuen PST, et al. Acute kidney injury biomarkers: needs, present status, and future promise. NephSAP 2006; 5:63-71. A review of novel biomarkers of AKI is presented.
8. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14:2534-2543.
9. Supavekin S, Zhang W, Kucherlapati R, et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003; 63:1714-1724.
10. Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24:307-315.
11. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophoreiron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610-621.
12. Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by NGAL. J Am Soc Nephrol 2004; 15:3073-3082.
13. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231-1238.
14. Wagener G, Jan M, Kim M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105:485-491.
15. Mishra J, Ma Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006; 21:856-863.
16. Parikh CR, Jani A, Mishra J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006; 6:1639-1645. In a multicenter study, urine NGAL and IL-18 levels were identified as promising biomarkers of delayed graft function after kidney transplantation.
17. Trachtman H, Christen E, Canaan A, et al. Urinary NGAL in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006; 21:989-994.
18. Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007; 22:2089-2095.
19. Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007; 11:R84. This prospective study identified NGAL as a promising biomarker that predicted development and severity of AKI in a heterogeneous cohort of critically ill patients with unknown timing of kidney injury.
20. Melnikov VY, Ecder T, Fantuzzi G, et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 2001; 107:1145-1152.
21. Parikh CR, Jani A, Melnikov VY, et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004; 43:405-414.
22. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005; 16:3046-3052.
23. Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199-203. NGAL and IL-18 were identified as early sequential biomarkers for AKI and adverse clinical outcomes.
24. Herget-Rosenthal S, Poppen D, Husing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50:552-558.
25. Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66:1115-1122.
26. Ahlstrom A, Tallgren M, Peltonen S, Pettila V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol 2004; 62:344-350.
27. Zhang Z, Humphreys BD, Bonventre JV. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol 2007; 18:2704-2714.
28. Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62:237-244.
29. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2007 [Epub ahead of print].
30. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18:904-912. This study showed that elevated urinary KIM-1 levels are associated with adverse outcomes in hospitalized patients who develop AKI.
31. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005; 16:3736-3741.
32. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007; 50:169-180.
33. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
34. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl 2004; 92:S76-S89.
35. de Zeeuw D, Ramjit D, Zhang Z, et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006; 69:1675-1682.
36. Mitsnefes MM, Kathman TS, Mishra J, et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007; 22:101-108. This study showed that serum NGAL outperforms cystatin C as a biomarker in CKD.
37. Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2007 [Epub ahead of print].
38. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007; 27:197-205.
39. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16:2449-2455.
40. Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006; 284 (1-2):175-182. This study identified urinary L-FABP as a biomarker in CKD.
41. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16:2456-2461.
42. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17:2176-2183.
43. Dent CL, Ma Q, Dastrala S, et al. Plasma NGAL predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007; 11:R127.
44. Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol (in press).